Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has submitted the first portion of its application seeking U.S. approval of QTORIN rapamycin, a treatment for microcystic lymphatic malformations, moving the company …
Palvella Begins FDA Filing for Rare Disease Drug Candidate Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has received U.S. Food and Drug Administration authorization for rolling review of its New Drug Application for QTORIN rapamycin, a step that could …
Palvella Secures FDA Rolling Review for Rare Disease Drug Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for its lead therapy targeting …
Palvella Advances Rare Disease Drug Toward FDA Filing Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) will present its development strategy to investors this week as the clinical-stage biotechnology company advances a pipeline of experimental treatments targeting rare dermatological …
Palvella Set for Goldman Conference Amid Rare Disease Push Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has secured a new U.S. patent covering a key treatment approach for porokeratosis, strengthening its intellectual property position as the company prepares to …
Palvella Secures Patent Protection Ahead of Rare Skin Trial Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) received the 2026 Healthcare & Life Sciences Company of the Year award from the Philadelphia Alliance for Capital and Technologies as the clinical-stage …
Palvella Wins PACT Award Amid Rare Disease Drug Push Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) reported new late-stage clinical data showing strong patient response rates for its experimental QTORIN rapamycin treatment in rare vascular malformations, positioning the company …
Palvella Reports Late-Stage Success for Rare Disease Drug Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) presented new Phase 2 data showing statistically significant reductions in lesion bleeding among patients treated with QTORIN rapamycin for cutaneous venous malformations, …
Palvella Advances Rare Disease Program With Phase 2 Data Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) transferred its stock listing to the Nasdaq Global Market this month after meeting stricter exchange requirements tied to market capitalization, liquidity, and …
Palvella Joins Nasdaq Global Market as Pipeline Advances Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for QTORIN rapamycin after reporting …
Palvella Eyes 2027 Launch After Positive Phase 3 Results Read More